Coherus Oncology (CHRS) Operating Income (2016 - 2025)
Historic Operating Income for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$44.3 million.
- Coherus Oncology's Operating Income rose 538.46% to -$44.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.7 million, marking a year-over-year increase of 5848.44%. This contributed to the annual value of -$111.7 million for FY2024, which is 4504.55% up from last year.
- Per Coherus Oncology's latest filing, its Operating Income stood at -$44.3 million for Q3 2025, which was up 538.46% from -$45.5 million recorded in Q2 2025.
- Coherus Oncology's 5-year Operating Income high stood at $42.6 million for Q4 2024, and its period low was -$167.4 million during Q1 2021.
- In the last 5 years, Coherus Oncology's Operating Income had a median value of -$45.4 million in 2025 and averaged -$51.1 million.
- In the last 5 years, Coherus Oncology's Operating Income plummeted by 50951.36% in 2021 and then skyrocketed by 16182.72% in 2024.
- Coherus Oncology's Operating Income (Quarter) stood at -$39.5 million in 2021, then plummeted by 30.21% to -$51.5 million in 2022, then plummeted by 33.81% to -$68.9 million in 2023, then surged by 161.83% to $42.6 million in 2024, then tumbled by 204.06% to -$44.3 million in 2025.
- Its Operating Income was -$44.3 million in Q3 2025, compared to -$45.5 million in Q2 2025 and -$45.4 million in Q1 2025.